Irinotecan sucrosofate
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Irinotecan sucrosofate
- Molecular weight
- 3,329.56
- Structure (SMILES)
- CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.O=S(=O)(O)OC[C@H]1O[C@@](COS(=O)(=O)O)(O[C@H]2O[C@H](COS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@H]2OS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@@H]1OS(=O)(=O)O
- irinotecan sucrosofate
- Irinotecan sucrosofate
- Irinotecan Sucrosofate
- IRINOTECAN SUCROSOFATE [USAN]
- Irinotecan sucrosofate [WHO-DD]
- irinotecan sucrosofate usan
- irinotecan sucrosofate who dd
- mm 398
- MM-398
- pep 02
- PEP-02
- pep02
- CAS registry numbers
- 1361317-83-0
- ChEMBL ID
- CHEMBL5314381
- InChIKey
- BCPSLKYBXGKPIW-RTXWKGGWSA-N
- PubChem compound IDs
- 76964235
- FDA ingredient codes (UNII)
- OL741S3N8B
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -tecan
Mechanisms of action
- Mechanism
- DNA topoisomerase I inhibitor
- Action type
- Inhibitor
- Target
- DNA topoisomerase 1
- Protein identifier
- P11387
Open Targets mechanisms
- Mechanism
- DNA topoisomerase I inhibitor
- Action type
- Inhibitor
- Target
- DNA topoisomerase 1
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Rectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000657
- Subject identifier
- D012004
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition identifier
- EFO_0003860
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000359
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001480
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002158
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003219
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005036
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005070
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005192
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006047
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006519
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0009831
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0015686
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0021040
- Highest recorded phase
- 3
- Event
- abdominal pain
- Reports
- 349
- Reporting signal score
- 114.509
- Event
- alopecia
- Reports
- 223
- Reporting signal score
- 121.526
- Event
- anaemia
- Reports
- 518
- Reporting signal score
- 303.38
- Event
- bone marrow failure
- Reports
- 138
- Reporting signal score
- 152.844
- Event
- cholinergic syndrome
- Reports
- 34
- Reporting signal score
- 107.176
- Event
- colorectal cancer metastatic
- Reports
- 62
- Reporting signal score
- 206.339
- Event
- decreased appetite
- Reports
- 437
- Reporting signal score
- 317.979
- Event
- dehydration
- Reports
- 289
- Reporting signal score
- 163.275
- Event
- dermatitis acneiform
- Reports
- 86
- Reporting signal score
- 179.622
- Event
- diarrhoea
- Reports
- 1,643
- Reporting signal score
- 1,415.08
- Event
- disease progression
- Reports
- 739
- Reporting signal score
- 1,181.56
- Event
- epistaxis
- Reports
- 185
- Reporting signal score
- 132.179
- Event
- febrile neutropenia
- Reports
- 435
- Reporting signal score
- 570.852
- Event
- gastrointestinal toxicity
- Reports
- 79
- Reporting signal score
- 171.785
- Event
- general physical health deterioration
- Reports
- 214
- Reporting signal score
- 154.885
- Event
- haematotoxicity
- Reports
- 110
- Reporting signal score
- 193.853
- Event
- headache
- Reports
- 82
- Reporting signal score
- 109.656
- Event
- hypertension
- Reports
- 408
- Reporting signal score
- 215.822
- Event
- intestinal obstruction
- Reports
- 111
- Reporting signal score
- 108.632
- Event
- leukopenia
- Reports
- 331
- Reporting signal score
- 395.033
- Event
- malignant neoplasm progression
- Reports
- 284
- Reporting signal score
- 302.542
- Event
- metastases to liver
- Reports
- 142
- Reporting signal score
- 265.622
- Event
- metastases to lung
- Reports
- 74
- Reporting signal score
- 120.989
- Event
- mucosal inflammation
- Reports
- 284
- Reporting signal score
- 463.529
- Event
- myelosuppression
- Reports
- 104
- Reporting signal score
- 162.77
And 11 more, listed on the interactive page.
- NCT01494506
- NCT02551991
- NCT02631733
- NCT02640365
- NCT02785068
- NCT04009876
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 227
- Molecular formula
- C144H174N16O59S8
- Monoisotopic mass
- 3326.8872715
- Natural product
- No
Related records
Trials (80)
- 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
- A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer
- A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer
- A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
- A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma
- A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
- A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
- A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
- A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
- A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors
- A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer
- A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
- A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors
- A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas
- Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
- AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
- BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
- Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas
- Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma
In development for (15)
- Cancer Phase 1
- Colorectal cancer Phase 1
- Exocrine pancreatic carcinoma Phase 3
- Fallopian tube cancer Phase 2
- Gastric adenocarcinoma Phase 2
- Gastric cancer Phase 1
- Gastroesophageal junction adenocarcinoma Phase 2
- Malignant pancreatic neoplasm Phase 3
- Neoplasm Phase 1
- Ovarian cancer Phase 2
- Pancreatic adenocarcinoma Phase 3
- Pancreatic ductal adenocarcinoma Phase 3
- Pancreatic neoplasm Phase 3
- Primary peritoneal carcinoma Phase 2
- Rectal cancer Phase 2
Targets (1)
- TOP1 DNA topoisomerase I inhibitor